Page last updated: 2024-12-10

taprostene

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID5311243
CHEMBL ID2104890
CHEBI ID197230
SCHEMBL ID364129
MeSH IDM0117465

Synonyms (28)

Synonym
gtpl1968
3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]methyl]benzoic acid
benzoic acid, 3-((4-(3-cyclohexyl-3-hydroxy-1-propenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)methyl)-, (3ar-(2z,3a-alpha,4-alpha(1e,3s*),5-beta,6a-alpha))-
taprostene [inn]
alpha-((2z,3ar,4r,5r,6as)-4-((1e,3s)-3-cyclohexyl-3-hydroxypropenyl)hexahydro-5-hydroxy-2h-cyclopenta(b)furan-2-ylidene)-m-toluic acid
taprostenum [latin]
taprosteno [spanish]
taprostene
3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]uran-2-ylidene]methyl]benzoic acid
CHEBI:197230
3-[(z)-[(3ar,4r,5r,6as)-4-[(e,3s)-3-cyclohexyl-3-hydroxyprop-1-enyl]-5-hydroxy-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]methyl]benzoic acid
cg 4203
CHEMBL2104890
108945-35-3
taprostenum
unii-7ms1hey2iz
taprosteno
7ms1hey2iz ,
rheocyclan
taprostene [mi]
SCHEMBL364129
J-002212
DTXSID50872496
Q27088939
3-((z)-((3ar,4r,5r,6as)-4-((s,e)-3-cyclohexyl-3-hydroxyprop-1-en-1-yl)-5-hydroxyhexahydro-2h-cyclopenta[b]furan-2-ylidene)methyl)benzoic acid
HY-114671
CS-0063760
AKOS040758543

Research Excerpts

Overview

Taprostene is a prostacyclin analogue that inhibits platelet aggregation. It might be a useful adjuvant to thrombolytic agents in acute myocardial infarction.

ExcerptReferenceRelevance
"Taprostene is a prostacyclin analogue that inhibits platelet aggregation and thus might be a useful adjuvant to thrombolytic agents in acute myocardial infarction. "( The effect of taprostene in patients with acute myocardial infarction treated with thrombolytic therapy: results of the START study. Saruplase Taprostene Acute Reocclusion Trial.
Bär, FW; Barth, H; Groves, R; Lange, S; Meyer, J; Michels, R; Uebis, R; Vermeer, F, 1993
)
2.09

Actions

ExcerptReferenceRelevance
"Taprostene did not increase the spontaneous lysis rate of the incorporated 125J-fibrin (7.3 +/- 1.4% vs 8.1 +/- 1.4%), but further enhanced the fibrinolytic effect of saruplase (37.2 +/- 5.6% saruplase vs 53.6 +/- 2.3% saruplase + taprostene; p less than 0.05)."( Taprostene, a stable prostacyclin analogue, enhances the thrombolytic efficacy of saruplase (recombinant single-chain urokinase-type plasminogen activator) in rabbits with pulmonary embolized thrombi.
Schneider, J, 1991
)
2.45
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
benzoic acidsAny aromatic carboxylic acid that consists of benzene in which at least a single hydrogen has been substituted by a carboxy group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (2)

Assay IDTitleYearJournalArticle
AID1346350Human IP receptor (Prostanoid receptors)1997Journal of cardiovascular pharmacology, Apr, Volume: 29, Issue:4
Relaxant actions of nonprostanoid prostacyclin mimetics on human pulmonary artery.
AID1346350Human IP receptor (Prostanoid receptors)2012Biochemical pharmacology, Jul-01, Volume: 84, Issue:1
Binding and activity of the prostacyclin receptor (IP) agonists, treprostinil and iloprost, at human prostanoid receptors: treprostinil is a potent DP1 and EP2 agonist.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (52)

TimeframeStudies, This Drug (%)All Drugs %
pre-199020 (38.46)18.7374
1990's22 (42.31)18.2507
2000's5 (9.62)29.6817
2010's5 (9.62)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 10.08

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index10.08 (24.57)
Research Supply Index4.22 (2.92)
Research Growth Index4.30 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (10.08)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials12 (21.82%)5.53%
Reviews3 (5.45%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other40 (72.73%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]